Tricuspid regurgitation (TR) is a cardiovascular disorder characterized by the reverse flow of blood through the tricuspid valve, which leads to its incomplete closure during right ventricular systole. This pathology can be both congenital and acquired, caused by various factors, including right ventricular dilation, inflammatory processes, and testing for infective endocarditis. The main manifestations of the disease are shortness of breath, fatigue, swelling of the lower extremities, and liver enlargement. Without proper treatment, regurgitation can lead to serious complications, including heart failure and atrial fibrillation.
History of the disease and interesting historical facts
The history of studying heart disease goes back to ancient times, when doctors tried to understand how the heart functions. The modern understanding of RVD began to take shape in the 19th century, when connections were established between valve pathology and clinical manifestations of diseases. René Laennec, a renowned anatomist and pathologist, described several cases of cardiovascular disease in the mid-19th century, including cases associated with valve regurgitation. In the 20th century, with the development of imaging technologies such as ultrasound, doctors were able to more accurately diagnose and examine heart disease. Over the past decades, numerous studies have been conducted that have contributed to a better understanding of the pathophysiology of RVD and the introduction of new treatment methods.
Epidemiology
According to epidemiological studies, tricuspid regurgitation has different prevalence depending on the age group and comorbidities. According to various sources, TCR occurs in 1-2% of the population, but among patients with heart failure, its prevalence increases significantly and reaches 30%. It is also observed that among patients with pulmonary hypertension, TCR occurs in more than 60% cases. It is important to note that with age, the risk of developing TCR increases, and in people over 70 years old, this figure can reach 15-20%.
Genetic predisposition to this disease
Genetic predisposition to tricuspid regurgitation may be due to a variety of factors, including inherited connective tissue disorders such as Marfan syndrome and Ehlers-Danlos syndrome. Mutations in genes that code for structural proteins such as fibrillin-1 (FBN1) and collagen (COL1A1) may lead to changes in valve structure and function. Studies show that a family history of connective tissue disorders significantly increases the risk of developing tricuspid regurgitation. The extent to which genetics influences this disorder requires further study, but it is known that adaptive changes in cardiac structure may develop in the context of genetic predispositions.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of tricuspid valve regurgitation:
- Inflammatory diseases of the heart, such as infective endocarditis.
- Pulmonary hypertension leading to right ventricular dilatation.
- Congenital heart defects such as atrial septal defect.
- Chest injuries that cause damage to the valves.
- Systemic diseases such as dwarfism, systemic lupus erythematosus, which can affect connective tissues.
It is important to note that the combination of several risk factors can significantly increase the likelihood of developing RTC and its clinical manifestations.
Diagnosis of this disease
Diagnosis of tricuspid valve regurgitation includes a variety of methods, including:
- Main symptoms: shortness of breath, fatigue, swelling, bruising, rapid heartbeat.
- Laboratory tests: complete blood count, biochemical markers, natriuretic peptide level.
- Radiological examinations: chest x-ray to assess the size of the heart.
- Other types of diagnostics: echocardiography, which allows visualization of anatomical structures and functional changes in the valves.
- Differential diagnosis: It is necessary to exclude other causes of cardiovascular failure, including stenosis, non-cardiac diseases and pulmonary diseases.
Echocardiography is the main method used to diagnose RTC, allowing to identify the degree of regurgitation and assess the condition of the heart.
Treatment
Treatment of tricuspid valve regurgitation can be either conservative or surgical.
- General treatment: symptom management, including control of oedema and dyspnea, and correction of comorbidities.
- Pharmacological treatment: use of diuretics to relieve edema, angiotensin antagonists and beta-blockers to improve cardiac function.
- Surgical treatment: In cases of severe regurgitation with obvious manifestations of heart failure, surgical correction or replacement of the tricuspid valve may be required.
- Other treatments: Measures to improve heart function, including physical activity and dietary therapy.
Surgical intervention is indicated in the presence of clinical manifestations of heart failure and a high degree of regurgitation.
List of medications used to treat this disease
Among the medications that can be used to treat tricuspid regurgitation are:
- Diuretics (eg, furosemide) to control swelling.
- Beta blockers (eg, metoprolol) to improve heart function.
- Angiotensin antagonists (eg, enalapril) to control blood pressure.
- Antiarrhythmic drugs (eg, amiodarone) to control the heart rhythm.
- Aspirin or anticoagulants to prevent blood clots.
The effectiveness of the use of drugs should always be strictly under the supervision of a physician to prevent complications.
Disease monitoring
Monitoring of patients with tricuspid valve regurgitation includes regular checks of the heart and symptom dynamics:
- Control stages: regular echocardiographic studies to assess the condition of the valves and the degree of regurgitation.
- Prognosis: With timely treatment and adequate monitoring of the condition, many patients are able to lead an active lifestyle.
- OSL complications: possible complications include the development of heart failure, arrhythmia and thrombosis, which requires active diagnosis and treatment adjustment.
It is important that patients with RTC be under constant medical supervision to adjust treatment and prevent worsening of the condition.
Age-related features of the disease
Tricuspid valve regurgitation may present differently depending on the age group:
- In children: less common, more often occurs against the background of congenital heart defects.
- In young people: may be associated with infective endocarditis and pulmonary diseases.
- In adults: most often develops against the background of chronic diseases such as hypertension and chronic heart failure.
- In the elderly: the incidence of regurgitation increases, often associated with stenosis and other cardiovascular diseases.
Understanding the age-related characteristics of the development of RTC allows for more effective planning of diagnostics and treatment.
Questions and Answers
- What is tricuspid regurgitation? Tricuspid regurgitation is a condition in which the valve does not close completely, causing blood to flow backward into the right atrium.
- What are the main symptoms of RTC? The main symptoms are shortness of breath, fatigue, swelling of the lower extremities and increased fatigue.
- How is this disease diagnosed? Diagnosis includes clinical examination, echocardiography and laboratory tests.
- What treatment is used for RTC? Treatment includes drug therapy, surgery, and control of the patient's symptoms.
- What is the prognosis for patients with tricuspid regurgitation? The prognosis depends on the severity of the disease and the presence of concomitant diseases, but with timely assistance, many patients can lead an active lifestyle.
